Coverage

23-Jun-2022

The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

Read More

5-Apr-2022

Digital pharma industry news site, Outsourcing-Pharma, spoke with Noxopharm CEO and Managing-Director, Dr Gisela Mautner about Veyonda®’s recent Orphan Drug Designation as a treatment for soft-tissue sarcoma.

Read More

31-Mar-2022

Australian biotech news site, Biotech Dispatch reported: US FDA grants new orphan designation to Noxopharm's Veyonda - Biotech

Read More

9-Mar-2022

Digital news site, Yahoo! Posted the following: Sarcoma trial cancer treatment begins at City of Hope in Los Angeles.

Read More

9-Mar-2022

Global business digital news site, Bloomberg, published the announcement regarding the commencement of Noxopharm’s new sarcoma trial.

Read More

9-Mar-2022

US clinical trial news site, Bioworld’s ‘In the Clinic for March 8-14 2022’ noted Noxopharm’s CEP2 trial initiation.

Read More

8-Mar-2022

Pharmaceutical news and industry site, Pharmiweb, provided this update on Noxopharm’s new sarcoma trial underway in the US.

Read More

8-Mar-2022

Life Sciences industry digital hub, BioSpace, reported “Sarcoma Trial for New Cancer Treatment Begins at City Of Hope (Hospital) in Los Angeles.

Read More

28-Feb-2022

The study investigates NOX's flagship treatment, Veyonda, in combination with the chemotherapy drug doxorubicin for the treatment of patients with soft tissue sarcoma, an aggressive cancer in urgent need of new treatment options.
Read More

22-Feb-2022

The company has a substantial arsenal of products and is channelling more funds into R&D to advance clinical trials, drug discovery and preclinical activities.
Read More